Skip to Main Content

Paper Details

Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program.
Drug Saf
4
2021
Author NameAffiliation
Ameet SarpatwariDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School
Joshua J GagneDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School
Aaron S KesselheimDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School
  • 1 - 3

Datasets

Release 1.2